Oncology

Latest News

Neoadjuvant radiotherapy was associated with longer time spent in the hospital and a higher risk of short- and long-term wound complications. | Image credit: cacaroot - stock.adobe.com
Radiotherapy Raises Risk of Complications After Limb STS Surgery

September 16th 2025

Patients who underwent neoadjuvant radiotherapy for soft tissue sarcoma (STS) spent longer in the hospital and were more likely to have wound complications.

AJMC Q&A with Danny Nguyen, MD | Background image credit: ipopba - stock.adobe.com
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD

September 15th 2025

The use of miRNA in situ hybridization shows clear subtype-specific miRNAs, which the authors said warrant further investigation. | Image credit: CrazyJuke - stock.adobe.com
miRNA Profiling May Unlock SCLC Biomarkers

September 13th 2025

Value-Based Care Veterans, Surprised by EOM Results, Ponder Next Move
Value-Based Care Veterans, Surprised by EOM Results, Ponder Next Move

September 11th 2025

FDA | Image credit: Postmodern Studio.jpeg
FDA Approves Selumetinib for Children With NF1 and Inoperable Tumors

September 10th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
September 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Site Logo
June 19th 2013

Aspirin May Slow DNA Mutations, Fight Cancer

Episode 14 - Conclusion: Final Thoughts Concerning Immunotherapy
June 19th 2013

Episode 14 - Conclusion: Final Thoughts Concerning Immunotherapy

Episode 13 - Healthcare Reform's Impact on Immunotherapy (Part 2)
June 19th 2013

Episode 13 - Healthcare Reform's Impact on Immunotherapy (Part 2)

Epsiode 12 - Healthcare Reform's Impact on Immunotherapy (Part 1)
June 19th 2013

Epsiode 12 - Healthcare Reform's Impact on Immunotherapy (Part 1)

Epsiode 11 - The Impact of Combination Therapies on Resource Allocations
June 19th 2013

Epsiode 11 - The Impact of Combination Therapies on Resource Allocations

Episode 10 - Measuring Economic Burden or Value Against Clinical Outcomes
June 19th 2013

Episode 10 - Measuring Economic Burden or Value Against Clinical Outcomes

Episode 9 - The Payer Approach to Immunotherapy
June 19th 2013

Episode 9 - The Payer Approach to Immunotherapy

Episode 8 - A Managed Care Approach to Immunotherapy
June 19th 2013

Episode 8 - A Managed Care Approach to Immunotherapy

Episode 7 - Immunotherapy: Where Is It At? Where Is It Headed?
June 19th 2013

Episode 7 - Immunotherapy: Where Is It At? Where Is It Headed?

Episode 6 - Recommended Guidelines and Payer Challenges
June 19th 2013

Episode 6 - Recommended Guidelines and Payer Challenges

Episode 5 - Recent Additions to the Pipeline
June 19th 2013

Episode 5 - Recent Additions to the Pipeline

Episode 4 - Pushing Reform through Immunotherapy
June 19th 2013

Episode 4 - Pushing Reform through Immunotherapy

Episode 3 - Managed Care Concerns and Treatment Accessibility
June 19th 2013

Episode 3 - Managed Care Concerns and Treatment Accessibility

Episode 1 - The Advent of Cancer Immunotherapy: Addressing Unmet Needs
June 19th 2013

Episode 1 - The Advent of Cancer Immunotherapy: Addressing Unmet Needs

Episode 2 - Diverse Applications Amidst a Growing Pipeline
June 19th 2013

Episode 2 - Diverse Applications Amidst a Growing Pipeline

Site Logo
June 19th 2013

Tailor Treatment Plans to Improve Outcomes in Managing NSCLC

Katie Sullivan
Site Logo
June 19th 2013

Looking at Specialty Pharmaceutical Rejections

Dea Belazi, PharmD, MPH
Site Logo
June 18th 2013

Third-Party Validation of Observed Savings From an Oncology Pathways Program

Bruce A. Feinberg, DO Scott Milligan, PhD Joseph Cooper, BS Winston Wong, PharmD Daniel Winn, MD Neil Schneider, ASA, MAAA Sheamus Parkes, FSA, MAAA Jeffrey Scott, MD
Site Logo
June 18th 2013

I-SPY Trials Seek Effective New Drug Combinations Using Adaptive Trial Design

Ben Leach
Site Logo
June 18th 2013

Observation of Prostate Cancer Both Effective and Cost-Efficient

Site Logo
June 17th 2013

Tailored Cancer Treatment Plans May Be Latest Trend

Site Logo
June 14th 2013

Proton Therapy Treatment Centers in Risk-sharing Health Systems

Katie Sullivan
Hospital systems across the country are increasingly vying to establish some of the first treatment centers to provide proton beam therapy, a high-tech radiation treatment for cancer.
Site Logo
June 13th 2013

Supreme Court Rules: No Patents for Human Genes

Site Logo
June 10th 2013

Immunotherapy Cancer Drugs Are Breakthrough, But Cost Is An Issue

Site Logo
June 7th 2013

More Cancer Specialist Nurses To Improve Hospital Care

Site Logo
June 6th 2013

PSA Screening: New Round Of Guidelines Emphasizes Importance Of Weighing Harms And Benefits

Site Logo
June 5th 2013

Trends in Patient Chemo Care Add Strain to Medicare

Dr. George Addresses Provider Issues Regarding Immunotherapies
June 3rd 2013

Dr. George Addresses Provider Issues Regarding Immunotherapies

Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer.
Dr. Kolodziej Discusses Personalized Medicine in Oncology
June 3rd 2013

Dr. Kolodziej Discusses Personalized Medicine in Oncology

Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that the rapid emergence of precision medicine was one of the more interesting topics discussed at the ASCO 2013 Annual Meeting.
Penn Survey Finds Cancer Drug Shortages Affect Treatment, Research
June 3rd 2013

Penn Survey Finds Cancer Drug Shortages Affect Treatment, Research

Ongoing shortages of common oncology chemotherapies have compelled physicians to substitute more expensive drugs, delay or suspend clinical trials, or even skip doses of chemotherapy, according to survey results gathered by a team from the University of Pennsylvania.
<1
...
175176177178179180181182183
...
188>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo